Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ON-01 and flucytosine in recurrent malignant glioma
NCT06562621Phase 2Completed
- Sponsor
- Beijing Neurosurgical Institute
- Start
- Aug 2018
- Primary completion
- Aug 2022
- Countries
- 1
01
Overview
Phase 2, open-label trial in malignant glioma and glioblastoma multiforme (GBM), sponsored by Beijing Neurosurgical Institute. Primary endpoint: Long term safety follow up at 5 years. Started Aug 2018; status: completed.
02
Conditions
malignant gliomaglioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT06562621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06562621.